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A B S T R A C T
The prevalence of the Panton–Valentine leukocidin (PVL) gene in Staphylococcus aureus was
investigated with a simple, reproducible and rapid real-time LightCycler SYBR Green I PCR assay.
The PVL gene was detected in one isolate from 65 patients with S. aureus bacteraemia, in four
isolates from 55 patients with respiratory tract infections, and in two isolates from 91 patients with
cutaneous infections. In contrast, 15 of 25 cutaneous isolates of methicillin-resistant S. aureus (MRSA)
were positive. All PVL-positive cutaneous MRSA isolates were community-acquired and com-
prised three different clones as determined by pulsed-field gel electrophoresis. The PVL gene was
detected in isolates from patients with recurrent primary skin infections and S. aureus bacteraemia,
but PVL did not seem to be an important virulence factor in the pathogenesis of staphylococcal
bacteraemia.
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I N T R O D U C T I O N
Staphylococcus aureus is an important human
pathogen that causes a diverse range of diseases,
from mild superficial skin infection to life-threat-
ening bacteraemia and infective endocarditis, as
well as toxin-mediated conditions such as toxic
shock syndrome [1]. S. aureus produces more than
30 different extracellular products [2]. Nearly all
strains secrete a group of enzymes and cytotoxins
that includes haemolysins (a, b, c and d), nucleas-
es, proteases, lipases, hyaluronidase and collage-
nase. Some strains produce one or more additional
exoproteins, which include toxic shock syndrome
toxin-1 (TSST-1), the staphylococcal enterotoxins
(SEA-E, G-I), the exfoliative toxins (ETA and ETB)
and Panton–Valentine leukocidin (PVL) [3].
PVL and c-haemolysin are considered to be
members of a toxin family known as synergo-
hymenotropic toxins, since they act on cell mem-
branes by the synergy of two proteins that form a
pore. Only 2% of S. aureus isolates produce PVL,
while c-haemolysin is produced by > 99% of
S. aureus isolates [4]. PVL is the most leukocyto-
lytic toxin in the family, but exhibits no haemo-
lytic activity on human erythrocytes [5]. It is also
dermo-necrotic, as observed after intradermal
injection of rabbit skin [6]. At sub-lytic concentra-
tions, PVL has been demonstrated to induce
granule secretion and release of leukotriene B4
and interleukin-8 from human polymorphonu-
clear leukocytes [4].
There are at least five different proteins in the
family, divided into two compatible classes,
termed S (slow-eluted) and F (fast-eluted) on the
basis of their separation by column chromatogra-
phy, namely HlgA, HlgC and LukS-PV (class S)
and HlgB and LukF-PV (class F) [4]. The LukS-PV
and LukF-PV components of PVL have been
purified from a V8 strain (ATCC 49775) and were
determined to be 32 and 38 kDa in size, respect-
ively [7]. The PVL genetic determinant contains
two open reading frames, lukS-PV and lukF-PV,
which are 939 and 978 nucleotides in size,
respectively, and are separated by a single
thymine nucleotide and transcribed as a single
mRNA molecule [4]. This gene has been found in
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different prophages on the genomes of different
S. aureus strains [8,9].
Most S. aureus strains responsible for primary
skin infections and necrotising pneumonia har-
bour the PVL determinant [10,11]. The PVL gene
has been detected in 93% of isolates associated
with furunculosis, 55% of isolates associated with
cellulitis, 50% of isolates associated with cutane-
ous abscess, and 13% of isolates associated with
finger-pulp infection, but was absent in isolates
associated with superficial folliculitis and impe-
tigo [11]. Highly lethal necrotising pneumonia
caused by PVL-positive S. aureus has been des-
cribed in previously healthy young patients [10].
In a study of 593 S. aureus isolates [12], 83 were
PVL-positive, and 14 of these were from patients
with community-acquired methicillin-resistant
S. aureus (CA-MRSA). Two patients with necrotis-
ing pneumonia have been identified in Sweden
[13], and one previously healthy patient presented
at O¨rebro University Hospital with a pulmonary
abscess caused by PVL-positive S. aureus. This
may represent an emerging problem with the
spread of PVL-positive S. aureus in the commu-
nity. Thus, a rapid and reliable method for
detecting PVL-positive isolates is required, as the
optimal therapy for this disease might be antimi-
crobial agents in combination with intravenous
immunoglobulin. The present study describes the
development of a rapid real-time LightCycler PCR
assay for detection of the PVL gene, and its use
for determining the frequency of PVL-positive
S. aureus isolates in a Swedish setting.
M A T E R I A L S A N D M E T H O D S
Bacterial isolates and patients
The bacteria investigated comprised S. aureus isolates identi-
fied and stored at the Department of Clinical Microbiology,
O¨rebro University Hospital, Sweden from 1999 to 2002
(Table 1). Some were from previous consecutive prospective
studies, while others were collected from the routine diagnos-
tic laboratory. Isolates from patients with S. aureus bacterae-
mia, skin infections or respiratory tract infections were
investigated. S. aureus strains were identified by conventional
methods, including DNase and coagulase tests. Colonies were
suspended in preservation medium (trypicase soy broth con-
taining yeast extract 0.3%w/v and horse serum 30% v/v) and
stored at ) 70C. The study was approved by the O¨rebro
ethical committee.
Bacteraemia isolates (n = 65) were collected from 65
patients diagnosed with S. aureus bacteraemia [14]. The
median age was 66 years (range: 10–91 years) and 59% were
men.
Consecutive S. aureus isolates (n = 43) from 39 patients with
cutaneous infections were collected for 2 days in September
2002. The isolates were from inpatients (n = 8) and outpatients
(n = 31). The median age of the patients was 66 years (range:
0.4–93 years) and 36% were men. A further 73 S. aureus
isolates obtained since 1999 from 68 patients with cutaneous
infections were also analysed. These isolates represented more
severe infections or unusual clinical findings, and included 25
MRSA isolates from 24 patients, which were hospital-acquired
(HA-MRSA) in six cases and CA-MRSA in 18 cases. The
median patient age was 33 years (range: 3 days to 88 years),
although 40% were aged < 10 years, and 41% were men.
Pulmonary infection isolates were obtained from the fol-
lowing sources:
1. Twenty-one patients included in a prospective study of
pneumonia aetiology conducted during 1999–2002 at the
Department of Infectious Diseases, O¨rebro University
Hospital. The median age of these patients was 71 years
(range: 52–93 years). Eighteen isolates were obtained from
the nasopharynx, by swab and ⁄ or aspiration. Five other
isolates were obtained from representative sputum sam-
ples, i.e., > 5 neutrophils ⁄ epithelial cell. In addition, eight
nasopharyngeal control isolates were obtained from adult
patients (n = 114) hospitalised for orthopaedic surgery or
urinary tract, soft tissue or bone infections without respir-
atory symptoms.
2. Twenty-five S. aureus isolates, including four MRSA, from
respiratory tract samples of 23 patients since 1999, were
analysed. Six isolates were from nasopharyngeal swabs,
two were from nasopharyngeal aspirates, three were from
sputum or bronchial secretions, and 14 were from pleural
effusions or lung abscesses. The median age of these
patients was 52 years (range: 0.1–89 years).
Table 1. Detection of the Panton–Valentine leukocidin
gene in Staphylococcus aureus isolates from patients with
bacteraemia, various cutaneous infections and pulmonary
infections
Type of infection
No. of
isolates
No. of
MRSA
isolates
No. of
PVL-positive
isolates
Bacteraemia 65 0 1
Complicated 45 0
Infective endocarditis 15 0
Cutaneous infection 116
Prospective study 43 0 1
Impetigo ⁄ SSSS 3
Chronic wound infection 21
Post-operative wound infection 4
Erysipelas ⁄ cellulitis 2
Skin abscesses 4 1
Ear secretion 3
Paronychia 1
Miscellaneous skin infections 5
Retrospective study 73 25 16
Impetigo ⁄ SSSS 15
Erysipelas ⁄ cellulitis 1
Ear secretion 3 1 1
Skin abscesses 5 1 1
Furunculosis 5 3 4
Miscellaneous skin infections 44 20 10
Pulmonary infection 55
Prospective study 23 0 2
Retrospective study 25 0 2
Pneumonia and bacteraemia 7 0 0
SSSS, staphylococcal scaled skin syndrome.
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3. A third group of isolates was obtained by searching a
database of all patients treated at the Department of
Infectious Diseases during the periods 1997–1998 and
2000–2002 for pulmonary infections and concurrent bacter-
aemia. Thirty-nine patients were identified, but S. aureus was
isolated in only seven cases from blood culture. Two of these
isolates had already been included in the previous group.
Detection of PVL gene
Genomic DNA was extracted from cultures grown on blood
agar by suspending a few colonies in sterile water and heating
at 98C for 15 min, and then centrifuging at 13 000 g for 30 s.
The supernatant (2 lL) was used for LightCycler (Roche
Diagnostics, Mannheim, Germany) PCR analysis.
Oligonucleotide primers (forward: 5¢-GTAAAATGTCTG-
GACATGATCCA-3¢; reverse: 5¢-CAA(C ⁄G)TGTATTGGA-
TAGCAAAAGC-3¢ (Scandinavian Gene Synthesis AB Ko¨ping,
Sweden)) were designed from sequences used in a previous
study [11] to amplify a region consisting of the last section
of lukS-PV and the beginning of lukF-PV [4,15]. The specificity of
the primers was assessed by performing a similarity search of
the National Centre for Biotechnology Information (NCBI)
sequence databases with the BLAST program (blastn) [15].
The PCR mastermix (20 lL) contained LightCycler FastStart
DNA Master SYBR Green I (Roche Diagnostics) with 4 mM
MgCl2, 0.7 lM forward primer and 0.5 lM reverse primer. The
LightCycler program consisted of 95C for 10 min, followed by
35 cycles of 95C for 10 s, 52C for 5 s and 72C for 18 s, with
single fluorescence acquisition at the end of each extension step.
Finally, a melting curve analysis was conducted by continuous
fluorescence acquisition during temperature elevation from
65C to 95C at 0.1C ⁄ s. This enabled an assessment of the
specificity of the amplification reaction, since the melting point is
determined by the length and GC content of a specific amplicon.
A PVL-positive S. aureus isolate (16575) [13] was used as a
positive extraction control in every amplification run. In
addition, a DNA extract (4 lg ⁄mL) prepared with the Dyna-
beads DNA DIRECT system I (Dynal, Oslo, Norway) was used
as a positive amplification control (8 ng DNA ⁄ reaction) in
every run. S. aureus strain CCUG 35601 (RS85) and molecular-
grade water were used as negative controls.
PCR specificity
The LightCycler amplicon from control isolate 16575 was
purified with the High Pure PCR Product Purification Kit
(Boehringer Mannheim, Indianapolis, IN, USA) and sequenced
using the same PCR primers with the BigDye Terminator
Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems,
Warrington, UK). The reactions were purified with a DyeEx
Spin Kit (QIAGEN, Hilden, Germany) before analysis on an
ABI PRISM 310 (PE Applied Biosystems). Sequence data were
compiled and analysed with ABI PRISM AutoAssembler DNA
Sequence Assembly Software (PE Applied Biosystems), and
compared with sequences in the NCBI databases with the
BLAST program (blastn) [15].
Pulsed-field gel electrophoresis
Preparation and SmaI digestion of bacterial DNA was per-
formed with the GenePath Group 1 Reagent Kit (Bio-Rad
Laboratories, Hercules, CA, USA), used according to the
manufacturer’s instructions, except that the agarose plugs
were washed six times. Analysis was on agarose 1% w ⁄v gels
in 0.5· TBE buffer (89 mM Tris-borate, 1 mM EDTA) at
6 V ⁄ cm with ramped pulse times of 5.3–34.9 s over 20 h using
a contour-clamped homogeneous electric field (GenePath
System; Bio-Rad). Restriction patterns were analysed with
GelCompar software v. 4.0 (Applied Maths, Kortrijk, Belgium),
but were finally documented by visual examination and
interpreted as recommended by Tenover et al. [16].
R E S U L T S
Amplification of the PVL gene
The S. aureus positive control isolate (16575) yielded
a 421-bp amplification product with the developed
LightCycler PCR, whereas no amplification was
observed with strain RS85 (Fig. 1). The sequence of
this amplicon was > 99% identical to three PVL
sequences published previously [8,9,17] and 98.6%
identical to a fourth sequence [4]. The positive
amplification control was amplified in each run
with a crossing point of 23 cycles and a melting
point (Tm) of 81.6 ± 0.4C (range: 80.9–82.2C). The
positive extraction control amplified in every run
showed a Tm of 81.5 ± 0.4C (range: 80.9–82.1C).
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Fig. 1. Melting curve (a) and melting peaks (b) for real-
time PCR using the LightCycler System with SYBR Green I
for detecting the PVL gene of Staphylococcus aureus. Lower
lines represent profiles obtained with negative controls.
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Detection of the PVL gene in bacteraemia
isolates
Of 65 S. aureus bacteraemia isolates, only one was
PVL-positive by LightCycler PCR (Table 1). The
patient was male, aged 62 years, with an infected
haematoma in the groin following percutaneous
transluminal coronary angioplasty. There was no
evidence of further complications. A blood cell
count showed no leukopenia on admission, but
did show slight thrombocytopenia. The strain did
not produce staphylococcal enterotoxins A–D or
TSST-1. Three S. aureus isolates from patients with
concomitant pneumonia were PVL-negative.
Detection of the PVL gene in cutaneous
infection isolates
Among the 43 clinical isolates collected consecu-
tively during 2 days of routine activity, only one
was PVL-positive. This was from a male infant
aged 5 months who was being treated as an
inpatient following two episodes of extensive
subcutaneous abscesses.
Of the 73 isolates stored since 1999, 16 were PVL-
positive by PCR. One was a methicillin-sensitive
isolate from a female aged 34 years with relapsing
folliculitis and a furuncle, while the other 15 were
MRSA isolates from patients (median age 17 years;
range 4–52 years; 53% male) with furunculosis
(n = 3), abscess (n = 1), ear secretion (n = 1) or
miscellaneous pyogenic skin infections (n = 10).
These PVL-positive isolates were all regarded
as CA-MRSA and belonged to three different
genotypes as determined by pulsed-field gel
electrophoresis (Fig. 2). Among the PVL-negative
isolates, three were CA-MRSA and seven were
HA-MRSA (obtained from six patients).
Detection of the PVL gene in pulmonary
infection isolates
Among the 23 isolates from 21 patients in the
prospective study of pneumonia aetiology, two
were PVL-positive (Table 1), while the eight
control isolates were PVL-negative. Of these 21
patients, 16 had X-ray verified pneumonia, of
whom nine had no microbiological cause identi-
fied apart from S. aureus. S. aureus was isolated
from the sputum of three of the nine patients
(sputum samples were not obtained from three
patients). One of the PVL-positive isolates was
from the sputum of a female, aged 52 years, who
was also serologically positive for influenza B.
The other was isolated from the nasopharynx of a
male aged 85 years with bronchitis. Haemophilus
influenzae was also isolated from sputum and the
nasopharynx. Both patients remained alive after
6 months.
Among the 25 respiratory tract isolates from
1999–2002, two were PVL-positive. One was
isolated from the pus of a pulmonary abscess in
a male aged 46 years, while the other was isolated
from the bronchoalveolar lavage of a female aged
3 years who was positive for human immunode-
ficiency virus and was hospitalised with diffuse
multilobar infiltrates.
None of the seven S. aureus isolates from
patients with simultaneous pneumonia and bac-
teraemia were positive for the PVL gene.
D I S C U S S I O N
The specific, simple and reliable PVL LightCycler
assay could be performed in < 2 h following the
identification of S. aureus in pure agar culture. The
method was less cumbersome than previous
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Fig. 2. Pulsed-field gel electrophor-
esis patterns of 24 methicillin-resist-
ant Staphylococcus aureus isolates
from cutaneous infections.
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techniques (e.g., immunodiffusion with rabbit
antibodies) and combined PCR amplification
and detection. It should therefore prove useful
for routine testing.
In the present study, the PVL gene was detec-
ted once among 65 S. aureus isolates collected
prospectively from septicaemic patients. This
finding was in agreement with previous studies
showing prevalences of 0–2% in positive blood
cultures [6,7,18,19]. In addition, none of the
S. aureus isolates causing infective endocarditis
was PVL-positive [11]. Thus, PVL does not seem
to represent an important virulence factor in
invasive bloodstream infections.
In cutaneous infections, PVL has been associ-
ated more frequently with direct invasion and
tissue destruction (e.g., necrotising primary skin
infections such as furunculosis) than with secon-
dary infections after skin injury [6,11,18,19]. PVL-
positive S. aureus is isolated rarely from cases of
folliculitis or impetigo [6,11,18,19]. In the present
study, the isolates collected consecutively from
cutaneous cultures mostly represented secondary
skin infections. However, the single PVL-positive
isolate was from a patient with two episodes of
extensive subcutaneous abscesses. Thus, this find-
ing is not in conflict with previous knowledge.
Among the 73 S. aureus isolates from cutaneous
cultures which had been stored for various
reasons, 16 were PVL-positive. According to
information received in the case referrals, most
isolates were associated with primary skin infec-
tions. Fifteen of these isolates was CA-MRSA, and
none of the six HA-MRSA isolates was PVL-
positive. Dufour et al. [12] reported similar find-
ings with French isolates. Fourteen cases of
community-acquired infection were reported,
caused by mecA- and PVL-positive S. aureus
isolates belonging to a single clone, but the 15
PVL-positive CA-MRSA isolates in the present
study belonged to three different pulsed-field gel
electrophoresis clones.
The presence of the PVL gene in S. aureus has
been associated previously with community-
acquired pneumonia [11]. Gillet et al. [10] repor-
ted that PVL-producing S. aureus strains caused
rapidly progressive, haemorrhagic, necrotising
pneumonia with a high mortality rate, mainly in
immunocompetent children and young adults.
Most cases had a preceding influenza-like syn-
drome (fever and cough with coryza or pharyn-
gitis), but no laboratory diagnostic procedures
were undertaken to verify this. In the present
investigation, one isolate was PVL-positive from
nine adult patients with verified pneumonia,
respiratory cultures yielding S. aureus, and no
laboratory evidence of other aetiologies. If the
diagnostic criteria for staphylococcal pneumonia
were restricted to include only those patients with
a positive sputum culture, one of three patients
yielded PVL-positive S. aureus. This patient
showed a significant rise in titre against influenza
B (1 ⁄ 160–1 ⁄ 640). The second patient had a high
single titre against influenza A (1 ⁄ 320), and the
third showed low titres in the acute-phase
serum against influenza A and B (1 ⁄ 20 and 1 ⁄ 40,
respectively). Thus, an influenza infection may
have preceded the development of these sta-
phylococcal pneumonias. No further data were
available on the two patients with PVL-negative
S. aureus, as they died within 11 days of admis-
sion. The patient with PVL-positive S. aureus
survived.
None of the eight control patients had PVL-
positive S. aureus isolated from the nasopharynx.
This is consistent with previous reports on
asymptomatic nasal carriers [18,19]. However, in
the present study, PVL-positive S. aureus was
isolated from the nasopharynx of one patient with
H. influenzae bronchitis; this may represent colo-
nisation of the upper respiratory tract.
In the group of 25 stored isolates from 23
patients, two were PVL-positive. The first patient
presented with a pulmonary abscess as well as
infiltrates (X-ray and CT scan) in the left lower
lobe, and had prodromal illness with flu-like
symptoms. The patient’s condition improved
following intravenous antibiotic treatment and
percutaneous drainage of pus from the lung
abscess. Microscopic examination of pus from
the abscess revealed disrupted leukocytes. This
patient had a long history of ulcers in the anterior
nares, and a culture from this location revealed a
PVL-positive S. aureus isolate 10 days after ter-
mination of antibiotic treatment. This may indi-
cate that this patient is a persistent carrier of a
PVL-positive strain. The second patient was
immunocompromised and showed miliary infil-
trates of the lungs. Bronchoscopy revealed that
the respiratory tract was unaffected, with no
haemorrhagic or necrotic alterations. Culture
from bronchoalveolar lavage showed heavy
growth of S. aureus as well as a-haemolytic
streptococci and yeast. No Pneumocystis carinii or
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Mycobacterium tuberculosis strains were isolated.
The infiltrates disappeared following treatment
with trimethoprim–sulphamethoxazole.
In contrast, autopsies of patients with necrotis-
ing pneumonia associated with PVL-positive
S. aureus have revealed extensive ulceration of
the entire respiratory tract, but lack of infiltration
by inflammatory cells, which could be caused by
the cytolytic properties of PVL. This indicates that
PVL is an important virulence factor in the
development of severe necrotising pneumonia,
particularly that affecting young patients, which
may represent a specific clinical entity [10].
However, in the present study, the median age
of the patients was relatively high and no young
adults were included, which may explain, in part,
the absence of necrotising pneumonia.
In conclusion, the LightCycler PCR assay was
found to be a simple, reproducible and rapid
method for detection of the PVL gene in S. aureus.
PVL-positive isolates were obtained from
patients with recurrent primary skin infections
and S. aureus pneumonia, but PVL did not seem to
be an important virulence factor in the pathogen-
esis of staphylococcal bacteraemia. Notably, all
the PVL-positive cutaneous MRSA isolates were
community-acquired and belonged to three dif-
ferent clones.
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